## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.27 indicates fundamental undervaluation. Quality metrics strong (ROE 136%, ROA 12%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-8.4% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($461.49)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 1)

**1. HCA’s Cash Machine Looks Cheap After A Healthy Run**
- Source: Finimize | 20251203T145120 | Somewhat-Bullish | Relevance: 100%
- HCA Healthcare, the largest for-profit hospital operator in the U.S., has shown strong recent performance with a 56.6% total return over 12 months and raised full-year guidance for 2025. Despite policy risks and labor cost inflation, its robust cash generation, strong margins, and perceived valuation discount make it an appealing opportunity for long-term investors, though the stock carries risks associated with leverage and regulatory uncertainty.

**2. HCA Healthcare Stock Near Record Highs: December 2025 Earnings, Forecasts and Policy Risks Explained**
- Source: ts2.tech | 20251203T003617 | Bullish | Relevance: 100%
- HCA Healthcare (NYSE: HCA) is approaching record highs in December 2025, driven by strong earnings growth, upgraded guidance, and a strategic focus on outpatient expansion. The article details HCA's financial performance, analyst sentiment, and potential policy risks like the expiration of ACA premium tax credits. While momentum is strong, some analysts suggest the stock might be overextended in the short term.

**3. HCA Healthcare (HCA) Stock on December 1, 2025: Near All‑Time Highs, Upgraded Guidance and What Comes Next**
- Source: ts2.tech | 20251201T225926 | Bullish | Relevance: 100%
- HCA Healthcare (HCA) stock approached all-time highs on December 1, 2025, driven by upgraded guidance, strong institutional interest, and robust financial performance. Third-quarter 2025 results exceeded expectations, leading to an increased full-year EPS forecast of $27-28 per share. Despite the significant rally, HCA's valuation remains at a discount to the broader market on key cash-flow metrics, even as analyst price targets lag the current stock price.

**4. J.W. Cole Advisors Inc. Sells 1,025 Shares of HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251201T115111 | Somewhat-Bullish | Relevance: 100%
- J.W. Cole Advisors Inc. reduced its stake in HCA Healthcare by selling 1,025 shares, while other major institutional investors significantly increased their holdings. The article also details recent insider selling by two executive VPs, HCA Healthcare's strong financial performance beating analyst expectations, and a declared quarterly dividend. Analyst ratings for HCA Healthcare remain largely positive with a "Moderate Buy" consensus.

**5. Global Retirement Partners LLC Invests $433,000 in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251201T090903 | Bullish | Relevance: 100%
- Global Retirement Partners LLC recently invested $433,000 in HCA Healthcare, Inc. by acquiring 1,131 shares in Q2 2025. HCA Healthcare has shown strong financial performance, beating quarterly estimates with $6.96 EPS and $19.16 billion revenue, and analysts have set a "Moderate Buy" consensus with a $474.53 target price. The article also details other institutional investments, analyst ratings, stock performance, dividend announcements, and recent insider trading activities.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | Wells Fargo | $431 | $412 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-8.4% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $15M sold (4 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.27 suggests fair value with growth premium. Forward P/E 16.4x stretched relative to 7% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $111.6B |
| Beta | 1.37 |
| 52W Range | $289.98 - $520.00 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.27 |
| Forward P/E | 16.4 |
| Current P/E | 17.6 |
| YoY Growth | 7.3% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 7.0% to -1.5% (-8.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.5pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.76), momentum weakening. RSI neutral at 55. OFD pattern: -FTH (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.48% (CS: 37) | Neutral |
| RSI_14 | 54.8 | Neutral |
| MACD Histogram | -0.76 | Bearish |
| vs SMA20 | 1.004x | Above |
| vs SMA50 | 1.069x | Above |
| vs SMA200 | 1.260x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $486.77
- **Stop Loss:** $461.49 (5.2% risk)
- **Target:** $537.33 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 37
- **Position Value:** $18,010.49
- **Portfolio %:** 18.01%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*